Class Action Lawsuit Filed Against Ardelyx Over Drug Guidance Misstatements
News related to:Ardelyx, Inc · 1 min read
NEW YORK, Sept. 18, 2026 /CourierPR/ -- A class action lawsuit has been filed against Ardelyx, Inc. (ARDX) in the United States District Court for the District of Massachusetts. The lawsuit alleges that the company provided misleading information to investors between January 13, 2025, and August 6, 2026. Gainey McKenna & Egleston, a law firm, is representing the plaintiffs in this case.
The complaint alleges that Ardelyx made overwhelmingly positive statements to investors while simultaneously disseminating false and misleading information about the company's commercial performance and growth prospects for its drugs XPHOZAH and IBSRELA. Specifically, the lawsuit claims that the company concealed significant barriers to patient access, such as increased payer-related utilization-management processes, stringent prior authorization requirements, and step edit requirements, which slowed new-patient starts and delayed prescription fulfillment.
The truth, as the complaint alleges, emerged on August 6, 2026, when Ardelyx issued a press release reducing its full-year 2026 IBSRELA revenue guidance and withdrawing its long-term XPHOZAH revenue guidance. The company attributed the reduction in IBSRELA revenue to the increased payer utilization-management processes that restricted patient access and slowed new-patient starts. The withdrawal of the long-term XPHOZAH revenue guidance was attributed to "evolving market dynamics" and uncertainty regarding future growth projections.
The lawsuit claims that the price of Ardelyx’s common stock declined dramatically following the release of this information. On August 6, 2026, the closing market price of Ardelyx’s stock was $4.87 per share. By August 7, 2026, the stock price had fallen to $4.00 per share, a decline of about 18% in just a single day.